Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy.
Follow him on Twitter @RealPatCampbell or reach him via email at [email protected].
On March 8, the American College of Rheumatology and the Vasculitis Foundation released new guidance for diagnosis and management of Kawasaki disease, which serves as the final companion piece to a trio of other ACR/VF vasculitis guidelines released in July 2021.
The ESTIMABL2 trial indicates a follow-up strategy not involving use of radioiodine was noninferior to ablation strategies with radioiodine for the occurrence of functional, structural, and biologic events up to 3 years after thyroidectomy.
A retrospective cohort study suggests use of GLP-1 RAs was associated with a 21% reduction in risk of all-cause mortality in patients with type 2 diabetes and advanced-stage chronic kidney disease compared with DPP-4 inhibitors.
A randomized trial comparing the effects of immediate testing and disclosure versus delayed testing, results suggest disclosing results of APOL1 testing led to reductions in blood pressure and meaningful lifestyle changes among patients with hypertension.
New research from the US CDC's COVID-19 Response Team details the increased risks of severe COVID-19 infection associated with congenital heart defects.
An analysis of data from more than 100k pregnant women suggests a history of spontaneous abortion was associated with an 18% increase in risk of subsequent gestational diabetes, with a history of multiple spontaneous abortions associated with an even greater risk.
Data from the DISCHARGE trial provides evidence demonstrating computed tomography could be a safe alternative to catheterization in patients with stable chest pain and suspected CAD.
A cross-sectional study of more than 70k women suggests those with long or irregular menstrual cycles were at a 22% greater risk of NAFLD.
Data from the VITAL-AF trial indicate universal screening with single-lead ECGs among patients 65 years and older in primary care settings did not significantly increase in new atrial fibrillation diagnoses, but was more effective in patients aged 85 years or older.
Results of the VISION Cardiac Surgery study indicate measurements of hs-TnI the first day after surgery could provide insight into the risk of mortality in the first 30 days after cardiac surgery.
Multiple organizations, including the American Diabetes Association and the Endocrine Society, have released statements backing President Biden's call for insulin co-pay caps during his State of the Union Address on March 1.
Announced on March 1, the Breakthrough Device Designation from the FDA allows for use of Dexcom CGM technology in in-hospital settings and at other healthcare facilities.
An analysis comparing those who switched against those who did not, results of the study suggest switching levothyroxine generics did not result in a negative impact on TSH levels in adult patients.
A review of data from the prospective SmartCare-CAD trial details the primary drivers of nonparticipation in telerehabilitation programs among patients with cardiovascular conditions.
A retrospective review with nearly a year of follow-up indicates nearly 40% of newly diagnosed diabetes at COVID-19 admission regressed to prediabetes or normoglycemia at follow-up, suggesting stress hyperglycemia induced by COVID-19-related acute stress could be driving rates of diagnosis.
The CRL for bardoxolone methyl for treatment of CKD caused by Alport syndrome comes less than 3 months after an FDA advisory committee voted unanimously against approval of Reata Pharmaceutical's once-daily, orally administered activator of Nrf2.
A meta-analysis of studies assessing presence of pathological eating behaviors and risk of diabetic retinopathy was associated with a more than 3-fold increase in risk of retinopathy.
Announced by Reata Pharmaceuticals on February 25, the Complete Response Letter from the FDA for bardoxolone methyl comes a little over 2 months after an FDA advisory committee voted unanimously against approval of the once-daily, orally administered activator of Nrf2.
New research suggests pregnancies conceived with assisted reproductive technology were associated with a more than doubling in risk for acute kidney injury.
A new study indicates a novel, 2-step deep learning algorithm developed using echocardiogram videos was able to identify left ventricular hypertrophy and the cause with greater accuracy than trained clinicians.
Announced on Feb. 24, the approval indicates the SGLT2 inhibitor for reducing risk of CV death and hospitalizations for heart failure in adults with heart failure and is supported by data from the EMPEROR-Preserved trial.
An analysis of data from more than 16,000 patients demonstrates the added benefit interventions delivered in primary care settings can have on physical activity levels among adult patients.
An analysis comparing 15-year outcomes following Ross procedure and biological or mechanical aortic valve replacement provides insight into the risk of mortality and other adverse outcomes associated with each procedure.
Data from an analysis of more than 150,000 patients suggests increased BMI was associated with more than a 3-fold increase in odds of diabetic nephropathy in patients with type 2 diabetes, but this effect was more apparent in women who experienced a 14-fold increase in odds of diabetic nephropathy.
An analysis of data from the National Inpatient Sample suggests pregnancies conceived by assisted reproductive technology carried a 1.7- and 2.5-fold increase in risk for arrhythmia and acute kidney injury compared to those conceived without ART.
Announced by Abbott on Feb. 21, the expanded indication for the CardioMEMS HF System now includes patients with NYHA Class II heart failure and those with worsening heart failure, which expands the potential patient population by 1.2 million additional patients.
Announced on Feb. 18, the t:connect mobile app, which pairs with the t:slim X2 insulin pump, is the first-ever FDA-cleared smartphone application capable of initiating insulin delivery on both iOS and Android operating systems, according to Tandem Diabetes Care.
A retrospective cohort study suggests users of DOACs were at a 16% lower risk of developing macrovascular complications, a 21% lower risk of microvascular complications, and a 22% lower risk of mortality compared with warfarin users among a population of patients with diabetes and atrial fibrillation.
A single-center retrospective analysis of data from an endocrinology clinic in Turkey provides insight into an apparent increase in diagnoses of idiopathic central precocious puberty.
A new study in JAMA Network Open provides an overview of the cost-effectiveness of icosapent ethyl at multiple prices in high-risk patients with hypertriglyceridemia despite statin therapy.
